AbbVie announces phase III data showing VENCLYXTO®▼(venetoclax) in combination with rituximab improves progression-free survival in previously treated chronic lymphocytic leukaemia

Document -

AbbVie announces phase III data showing VENCLYXTO®▼(venetoclax) in combination with rituximab improves progression-free survival in previously treated chronic lymphocytic leukaemia

Phase III MURANO results presented for the first time as one of six late breaking abstracts during the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta
  • License: All rights reserved
    The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
  • File format: .pdf

Contacts

General Press Enquiries

Press contact 01628 925200

Joanna Jones

Press contact Head of Brand Communications and Patient Relations 07795 590 344

Cheryl Pitcher

Press contact Senior Corporate Communications Manager Internal and Corporate Communications 07500 786 466

Natalie Bennett

Press contact Senior Communications and Patient Relations Manager Immunology - Gastroenterology & Rheumatology 07818 428 074

Sarah Beck

Press contact Senior Brand Communications and Patient Relations Manager, Dermatology Dermatology 07818 428 111

Related content

AbbVie announces phase III data showing VENCLYXTO®▼(venetoclax) in combination with rituximab improves progression-free survival in previously treated chronic lymphocytic leukaemia

Phase III MURANO results presented for the first time as one of six late breaking abstracts during the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta